Overview
The Emerging Role of the Gut Microbiome in Reducing Recurrence of C. difficile Infection
Live Symposium at ACG 2019 October 28, 2019 in San Antonio, TX
Registration is closed for this activity.
Faculty will conduct a roundtable symposium on recurrent C. difficile infection including its etiology and burden, risk factors, the role of the gut microbiome, guideline-directed therapy, and new and emerging choices to reduce recurrent infection. The panel will also present patient cases of recurrent infections to discuss application of current guidelines and clinical trial data on emerging treatments.
This activity is intended for gastroenterologists, ID specialists, hospitalists, internists, physicians and other clinicians who care for patients at risk of serious gastrointestinal infection.
Recurrent episodes of C. difficile continue to pose a significant burden on patients, clinicians, and the healthcare system despite some progress. Clinicians must be familiar with risk factors across diverse patient populations to select appropriate therapy to reduce recurrence. Novel approaches, such as microbiome restoration therapy, are also under investigation, and clinicians must be familiar with these emerging treatments to reduce complications and improve clinical outcomes.
Upon completion of this activity, participants will be able to:
• Evaluate the role of the gut microbiome in relationship to C. difficile infection and approaches to reducing recurrent infection
• Discuss clinical risk factors that increase a patient’s risk for recurrent and multiply recurrent C. difficile infection
• Review guideline recommendations for the management of first and subsequent recurrences of C. difficile infection
• Describe available and emerging approaches for patients with recurrent C. difficile who have failed appropriate antibiotic therapy
• Evaluate the role of the gut microbiome in relationship to C. difficile infection and approaches to reducing recurrent infection
• Discuss clinical risk factors that increase a patient’s risk for recurrent and multiply recurrent C. difficile infection
• Review guideline recommendations for the management of first and subsequent recurrences of C. difficile infection
• Describe available and emerging approaches for patients with recurrent C. difficile who have failed appropriate antibiotic therapy
Grand Hyatt San Antonio / Texas Ballroom A
600 Market St.
San Antonio , TX USA
Click here to view location map
600 Market St.
San Antonio , TX USA
Click here to view location map
7:00 pm – 7:30 pm - Registration & Dinner
7:30 pm – 7:35 pm - Welcome & Introductions
7:35 pm – 7:55 pm - The Changing Epidemiology of C. difficile
7:55 pm – 8:15 pm - The Evolution of Treatment Options for C. difficile and Recurrent Disease
8:15 pm – 8:35 pm - Breaking the Cycle of Recurrence: Available and Emerging Approaches Beyond Antibiotic Therapy
8:35 pm – 8:50 pm - Panel Discussion
8:50 pm – 9:00 pm - Questions and Answers
7:30 pm – 7:35 pm - Welcome & Introductions
7:35 pm – 7:55 pm - The Changing Epidemiology of C. difficile
7:55 pm – 8:15 pm - The Evolution of Treatment Options for C. difficile and Recurrent Disease
8:15 pm – 8:35 pm - Breaking the Cycle of Recurrence: Available and Emerging Approaches Beyond Antibiotic Therapy
8:35 pm – 8:50 pm - Panel Discussion
8:50 pm – 9:00 pm - Questions and Answers
Sponsored by the Academy for Continued Healthcare Learning (ACHL).
Supported by an educational grant from Ferring Pharmaceuticals, Inc.
This event is neither sponsored by nor endorsed by ACG.
Paul Feuerstadt, MD, FACG
Gastroenterology Center of Connecticut
Assistant Clinical Professor of Medicine
Yale University School of Medicine
Hamden, CT
Gastroenterology Center of Connecticut
Assistant Clinical Professor of Medicine
Yale University School of Medicine
Hamden, CT
Sahil Khanna, MBBS, MS
Associate Professor of Medicine
Gastroenterology and Hepatology
Mayo Clinic
Rochester, MN
Gautam Mankaney, MD
Cleveland Clinic
Cleveland, OH
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.
The following financial relationships have been provided:
Paul Feuerstadt, MD, FACG (Faculty)
Consulting Agreements: Merck and Company, Ferring Pharmaceuticals, Inc., Roche Diagnostics
Speakers' Bureau: Merck and Company
Sahil Khanna, MBBS, MS (Faculty)
Sources of Funding for Research: Ferring Pharmaceuticals, Inc., Rebiotix, Inc
Consulting Agreements: Facile Therapeutics, Inc., Premier Inc., Probiotech LLC, Shire PLC
Gautam Mankaney, MD
Faculty disclosures not available at this time
Faculty disclosures not available at this time
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Investigational approaches to treating C. difficile infection and reducing recurrent episodes
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
Please note: Presentation slides may not reflect printed slides.
To receive credit, participants are required to participate in the live activity and complete the posttest, and evaluation and submit on-site. A certificate will be emailed to participants within 6 weeks. There is no fee to participate in the activity or for the generation of the certificate.
Inquiries may be directed to ACHL at (877) 444-8435, ext. 160.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Academy for Continued Healthcare Learning designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.